Table 1 Summary of study characteristics
Study characteristics | N (%) |
|---|---|
Total number of included studies | 150 (100.0) |
Publication year | |
 2020 | 11 (7.3) |
 2021 | 87 (58.0) |
 2022 | 35 (23.3) |
 2023 | 17 (11.3) |
Preprint | |
 Yes | 10 (6.7) |
 No | 140 (93.3) |
Study design | |
 Cross-sectional | 17 (11.3) |
 Prospective cohort | 98 (65.3) |
 Retrospective cohort | 24 (16.0) |
 Other designsa | 11 (7.4) |
Sampling representativeness | |
 Online surveys and single-hospital studies | 66 (44.0) |
 Multiple-hospital and regional studiesb | 63 (42.0) |
 National studies | 21 (14.0) |
Continent | |
 America | 42 (28.0) |
 Asia | 23 (15.3) |
 Europe | 80 (53.3) |
 Other continentsc | 5 (3.4) |
Sample size | |
 30–99 | 17 (11.3) |
 100–999 | 79 (52.7) |
  ≥ 1000 | 54 (36.0) |
Age groupd | |
 Children (0–14) | 8 (5.3) |
 Youth (15–24) | 1 (0.7) |
 Adults (25–64) | 114 (76.0) |
 Senior (65 +) | 16 (10.7) |
 Not reported | 11 (7.3) |
COVID-19 testing method | |
 Clinically confirmede | 130 (86.7) |
 Self-reported | 6 (4.0) |
 Not reported | 14 (9.3) |
Symptom assessment method | |
 Clinically evaluated | 74 (49.3) |
 Self-reported | 72 (48.0) |
 Other methods or not reported | 4 (2.7) |
Index date of follow-up | |
 Symptom onset/time at first diagnosis | 88 (58.7) |
 Hospitalization admission | 12 (8.0) |
 Hospitalization discharge | 41 (27.3) |
 Other index dates or not reported | 9 (6.0) |
Hospitalization status | |
 Inpatient | 54 (36.0) |
 Outpatient | 20 (13.3) |
 Mixed | 69 (46.0) |
 Not reported | 7 (4.7) |
COVID-19 severity of cases | |
 Mild | 5 (3.3) |
 Severe | 8 (5.3) |
 Mild to severe | 105 (70.1) |
 Not reported | 32 (21.3) |